Radiopharmaceutical Treatment of Malignant Pheochromocytoma

Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent cou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 1984-02, Vol.25 (2), p.197
Hauptverfasser: Sisson, James C, Shapiro, Brahm, Beierwaltes, William H, Glowniak, Jerry V, Nakajo, Masayuki, Mangner, Thomas J, Carey, James E, Swanson, Dennis P, Copp, Jean E, Satterlee, Winston G, Wieland, Donald M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 197
container_title The Journal of nuclear medicine (1978)
container_volume 25
creator Sisson, James C
Shapiro, Brahm
Beierwaltes, William H
Glowniak, Jerry V
Nakajo, Masayuki
Mangner, Thomas J
Carey, James E
Swanson, Dennis P
Copp, Jean E
Satterlee, Winston G
Wieland, Donald M
description Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.
format Article
fullrecord <record><control><sourceid>pubmed_highw</sourceid><recordid>TN_cdi_pubmed_primary_6726430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6726430</sourcerecordid><originalsourceid>FETCH-LOGICAL-h237t-75165c4c39077fad569c8daa037232e0d0539821ae7bb7d521e6d7b4a9b225b73</originalsourceid><addsrcrecordid>eNotj11LwzAYhYMos05_gtAr7wr56Ju0eCVDnTBRZF6Xt0m6ZjRNSVtk_97CdnU4PIcDzxVJGAjIQEp1TRLKJMsAKNySu3E8UkplURQrspKKy1zQhDz_oHFhaDF61HaenMYu3UeLk7f9lIYm_cTOHXpcyndrg25j8EGfpuDxntw02I324ZJr8vv2ut9ss93X-8fmZZe1XKgpU8Ak6FyLkirVoAFZ6sIgUqG44JYaCqIsOEOr6loZ4MxKo-ocy5pzqJVYk8fz7zDX3ppqiM5jPFUXiYU_nXnrDu2fi7bqZ93ZRWkZH3vPoeIVK5X4B3OSUY8</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</creator><creatorcontrib>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</creatorcontrib><description>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 6726430</identifier><language>eng</language><publisher>United States: Soc Nuclear Med</publisher><subject>3-Iodobenzylguanidine ; Adolescent ; Adrenal Gland Neoplasms - diagnostic imaging ; Adrenal Gland Neoplasms - radiotherapy ; Adult ; Aged ; Drug Evaluation ; Female ; Humans ; Iodine Radioisotopes - administration &amp; dosage ; Iodine Radioisotopes - adverse effects ; Iodobenzenes - administration &amp; dosage ; Iodobenzenes - adverse effects ; Male ; Middle Aged ; Neoplasm Metastasis ; Pheochromocytoma - diagnostic imaging ; Pheochromocytoma - radiotherapy ; Radionuclide Imaging ; Radiotherapy Dosage ; Time Factors</subject><ispartof>The Journal of nuclear medicine (1978), 1984-02, Vol.25 (2), p.197</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6726430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sisson, James C</creatorcontrib><creatorcontrib>Shapiro, Brahm</creatorcontrib><creatorcontrib>Beierwaltes, William H</creatorcontrib><creatorcontrib>Glowniak, Jerry V</creatorcontrib><creatorcontrib>Nakajo, Masayuki</creatorcontrib><creatorcontrib>Mangner, Thomas J</creatorcontrib><creatorcontrib>Carey, James E</creatorcontrib><creatorcontrib>Swanson, Dennis P</creatorcontrib><creatorcontrib>Copp, Jean E</creatorcontrib><creatorcontrib>Satterlee, Winston G</creatorcontrib><creatorcontrib>Wieland, Donald M</creatorcontrib><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</description><subject>3-Iodobenzylguanidine</subject><subject>Adolescent</subject><subject>Adrenal Gland Neoplasms - diagnostic imaging</subject><subject>Adrenal Gland Neoplasms - radiotherapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - administration &amp; dosage</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Iodobenzenes - administration &amp; dosage</subject><subject>Iodobenzenes - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Pheochromocytoma - diagnostic imaging</subject><subject>Pheochromocytoma - radiotherapy</subject><subject>Radionuclide Imaging</subject><subject>Radiotherapy Dosage</subject><subject>Time Factors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotj11LwzAYhYMos05_gtAr7wr56Ju0eCVDnTBRZF6Xt0m6ZjRNSVtk_97CdnU4PIcDzxVJGAjIQEp1TRLKJMsAKNySu3E8UkplURQrspKKy1zQhDz_oHFhaDF61HaenMYu3UeLk7f9lIYm_cTOHXpcyndrg25j8EGfpuDxntw02I324ZJr8vv2ut9ss93X-8fmZZe1XKgpU8Ak6FyLkirVoAFZ6sIgUqG44JYaCqIsOEOr6loZ4MxKo-ocy5pzqJVYk8fz7zDX3ppqiM5jPFUXiYU_nXnrDu2fi7bqZ93ZRWkZH3vPoeIVK5X4B3OSUY8</recordid><startdate>198402</startdate><enddate>198402</enddate><creator>Sisson, James C</creator><creator>Shapiro, Brahm</creator><creator>Beierwaltes, William H</creator><creator>Glowniak, Jerry V</creator><creator>Nakajo, Masayuki</creator><creator>Mangner, Thomas J</creator><creator>Carey, James E</creator><creator>Swanson, Dennis P</creator><creator>Copp, Jean E</creator><creator>Satterlee, Winston G</creator><creator>Wieland, Donald M</creator><general>Soc Nuclear Med</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>198402</creationdate><title>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</title><author>Sisson, James C ; Shapiro, Brahm ; Beierwaltes, William H ; Glowniak, Jerry V ; Nakajo, Masayuki ; Mangner, Thomas J ; Carey, James E ; Swanson, Dennis P ; Copp, Jean E ; Satterlee, Winston G ; Wieland, Donald M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h237t-75165c4c39077fad569c8daa037232e0d0539821ae7bb7d521e6d7b4a9b225b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>3-Iodobenzylguanidine</topic><topic>Adolescent</topic><topic>Adrenal Gland Neoplasms - diagnostic imaging</topic><topic>Adrenal Gland Neoplasms - radiotherapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - administration &amp; dosage</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Iodobenzenes - administration &amp; dosage</topic><topic>Iodobenzenes - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Pheochromocytoma - diagnostic imaging</topic><topic>Pheochromocytoma - radiotherapy</topic><topic>Radionuclide Imaging</topic><topic>Radiotherapy Dosage</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sisson, James C</creatorcontrib><creatorcontrib>Shapiro, Brahm</creatorcontrib><creatorcontrib>Beierwaltes, William H</creatorcontrib><creatorcontrib>Glowniak, Jerry V</creatorcontrib><creatorcontrib>Nakajo, Masayuki</creatorcontrib><creatorcontrib>Mangner, Thomas J</creatorcontrib><creatorcontrib>Carey, James E</creatorcontrib><creatorcontrib>Swanson, Dennis P</creatorcontrib><creatorcontrib>Copp, Jean E</creatorcontrib><creatorcontrib>Satterlee, Winston G</creatorcontrib><creatorcontrib>Wieland, Donald M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sisson, James C</au><au>Shapiro, Brahm</au><au>Beierwaltes, William H</au><au>Glowniak, Jerry V</au><au>Nakajo, Masayuki</au><au>Mangner, Thomas J</au><au>Carey, James E</au><au>Swanson, Dennis P</au><au>Copp, Jean E</au><au>Satterlee, Winston G</au><au>Wieland, Donald M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiopharmaceutical Treatment of Malignant Pheochromocytoma</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>1984-02</date><risdate>1984</risdate><volume>25</volume><issue>2</issue><spage>197</spage><pages>197-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[131I] iodobenzylguanidine (I-131 MIBG ), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8-11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumors declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.</abstract><cop>United States</cop><pub>Soc Nuclear Med</pub><pmid>6726430</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof The Journal of nuclear medicine (1978), 1984-02, Vol.25 (2), p.197
issn 0161-5505
1535-5667
language eng
recordid cdi_pubmed_primary_6726430
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects 3-Iodobenzylguanidine
Adolescent
Adrenal Gland Neoplasms - diagnostic imaging
Adrenal Gland Neoplasms - radiotherapy
Adult
Aged
Drug Evaluation
Female
Humans
Iodine Radioisotopes - administration & dosage
Iodine Radioisotopes - adverse effects
Iodobenzenes - administration & dosage
Iodobenzenes - adverse effects
Male
Middle Aged
Neoplasm Metastasis
Pheochromocytoma - diagnostic imaging
Pheochromocytoma - radiotherapy
Radionuclide Imaging
Radiotherapy Dosage
Time Factors
title Radiopharmaceutical Treatment of Malignant Pheochromocytoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T23%3A59%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiopharmaceutical%20Treatment%20of%20Malignant%20Pheochromocytoma&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Sisson,%20James%20C&rft.date=1984-02&rft.volume=25&rft.issue=2&rft.spage=197&rft.pages=197-&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/&rft_dat=%3Cpubmed_highw%3E6726430%3C/pubmed_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6726430&rfr_iscdi=true